Previous 10 | Next 10 |
Eagle Pharmaceuticals, Inc. (EGRX) Q2 2019 Earnings Conference Call August 08, 2019, 08:30 ET Company Participants Lisa Wilson - IR Scott Tarriff - CEO & Director Pete Meyers - CFO Conference Call Participants Ashley Ryu - RBC Capital Markets Brandon Folkes - Cantor F...
Eagle Pharmaceuticals ( EGRX ) Q2 results : Revenues: $56.7M (-4.4%); Product sales: $29.4M (+27.8%); Royalty revenue: $27.3M (-24.8%). More news on: Eagle Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...
Eagle Pharmaceuticals (NASDAQ: EGRX ): Q2 Non-GAAP EPS of $0.84 beats by $0.01 ; GAAP EPS of $0.48 beats by $0.17 . More news on: Eagle Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
-- Q2 2019 net income of $0.49 per basic and $0.48 per diluted share and adjusted non-GAAP net income of $0.86 per basic and $0.84 per diluted share -- -- Announced clinical development plan for its innovative fulvestrant program intended to deliver maximum estrogen receptor inhibition ...
Eagle Pharmaceuticals (NASDAQ: EGRX ) announces a clinical development plan to support the submission of a NDA for its fulvestrant formulation. More news on: Eagle Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
-- Eagle plans to conduct a Pilot Study shortly followed by a Pivotal Trial -- -- Pivotal Trial expected to be completed within approximately 12 months of commencing enrollment -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today a...
Eagle Pharmaceuticals, Inc. ("Eagle" or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2019 second quarter financial results on Thursday, August 8, 2019, before the market opens. Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief ...
The healthcare sector is underperforming the market by a wide margin on a year to date basis. The Healthcare Select Sector ETF ( XLV ) has gained 5.2%, while the SPDR S&P 500 ( SPY ) is up by almost three times that, with a cumulative gain of 15.1% in the same period. Data by YCharts ...
The following slide deck was published by Eagle Pharmaceuticals, Inc. in conjunction with this Read more ...
Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) announced today that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the Jefferies 2019 Global Healthcare Conference as follows: The present...
News, Short Squeeze, Breakout and More Instantly...
Eagle Pharmaceuticals Inc. Company Name:
EGRX Stock Symbol:
NASDAQ Market:
Eagle Pharmaceuticals Inc. Website:
2024-07-27 11:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-17 12:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-07 19:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...